| 证券代码 | XLRN.O |
| 证券名称 | Acceleron Pharma Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-09-19 |
| 首发价格(元) | 15 USD |
| 首发数量(股) | 5580000 |
| 首发募资额(元) | 83,700,000.00 USD |
| 首发主承销商 | Citigroup Global Markets Inc,Leerink Swann LLC |
| 货币单位 | USD |
| 公司名称 | Acceleron Pharma Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 128 Sidney Street, Cambridge, Massachusetts, USA |
| 成立日期 | 2003-06 |
| 董事会主席 | Francois Nader |
| 公司属地 | United States 美国 |
| 公司网址 | www.acceleronpharma.com |
| 电话 | +1 (617) 649-9200 |
| 传真 | - |
| 公司简介 | Acceleron Pharma Inc. is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with sotatercept in pulmonary arterial hypertension. |